Zobrazeno 1 - 10 of 15 pro vyhledávání: '"R C Horns"'
1
Resource utilization requirements for personalized cancer care, translational research, and clinical trial (CT) implementation
Autor: Swapnil Rajurkar, R. C. Horns, F. Howard, S. W. Kim, B. Ebrahimi, Cary A. Presant, G. Upadhyaya, D. Malouf, Linda D. Bosserman
Publikováno v: Journal of Clinical Oncology. 28:e16524-e16524
e16524 Background: There has been an increase in CTs of personalized cancer care laboratory assays which may predict clinical response. The goal of this study was to identify resources necessary to...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95b6cffb6238d37e7ddccd48beaf9976
https://doi.org/10.1200/jco.2010.28.15_suppl.e16524
Zobrazit plný text záznamu
2
Compliance (COMP) with colon cancer (CoC) national guidelines (NG) for chemotherapy (CT) by implementing electronic medical records (EMR)
Autor: R. C. Horns, W. McNatt, Linda D. Bosserman, Christina Yeon, B. Ebrahimi, B. Emilio, G. Upadhyaya, Cary A. Presant, M. J. Vakil, F. Howard
Publikováno v: Journal of Clinical Oncology. 26:17527-17527
17527 Background: Quality of care (QC) improves when NG are followed in patient (pt) management. Demonstration of COMP with NG is costly and slow (QOPI, and ASCO 2007 abstract 17050). We extended o...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a7f90a728e0e6809b427274f41ff291b
https://doi.org/10.1200/jco.2008.26.15_suppl.17527
Zobrazit plný text záznamu
3
Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): Frequency and characterization in clinical practice
Autor: R. C. Horns, F. Howard, Christina Yeon, A. Rios, Linda D. Bosserman, B. Ebrahimi, C. Kelly, M. J. Vakil, G. Upadhyaya, Cary A. Presant
Publikováno v: Journal of Clinical Oncology. 24:6137-6137
6137 Background: Prior studies of AI have identified A and/or BP as side effects. Reported incidences have varied from 4% (IMPACT) to 35.6% (ATAC). In order to determine the frequency of A or BP in clinical practice, we reviewed a consecutive series
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95b51ef12e0b2a5c10e3655718249b4d
https://doi.org/10.1200/jco.2006.24.18_suppl.6137
Zobrazit plný text záznamu
4
Heterogeneous monitoring for and management of bevacizumab (BE) toxicity (T): Develpment of standardized guidelines for monitoring (mon) and treatment (tre) of the BE toxicity syndrome (BETS)
Autor: M. J. Vakil, G. Upadhyaya, Linda D. Bosserman, C. L. Martel, Cary A. Presant, B. Ebrahimi, R. C. Horns
Publikováno v: Journal of Clinical Oncology. 23:8224-8224
8224 Background: BE is widely used for managing metastatic colorectal cancer and is in widespread trials including breast, lung, renal and lymphoid malignancies. Analysis of patients (pts) receivin...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a5f17cdfad563f16066580a149ad32a4
https://doi.org/10.1200/jco.2005.23.16_suppl.8224
Zobrazit plný text záznamu
5
Development and implementation of effective quality (Q) guidelines (G) in community (com) cancer centers (CC): The cancer quality program (CQP)
Autor: R. C. Horns, G. Upadhyaya, M. D. Scalia, B. Ebrahimi, Christina Yeon, Linda D. Bosserman, C. L. Martel, M. J. Vakil, T. Young, Cary A. Presant
Publikováno v: Journal of Clinical Oncology. 23:6105-6105
6105 Background: National panels, institutes, and media have accused oncology of poor Q in patient (pt) care. In order to improve Q in com pt care, we developed the CQP. Methods: 8 oncologists and ...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e7d40fb485fb1a38bb3ca352c47c2e6
https://doi.org/10.1200/jco.2005.23.16_suppl.6105
Zobrazit plný text záznamu
6
Incidence of bevacizumab (BE) related toxicities: Association of hypertension (HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS)
Autor: Linda D. Bosserman, R. C. Horns, G. Upadhyaya, M. J. Vakil, Christina Yeon, Cary A. Presant, B. Ebrahimi, C. L. Martel
Publikováno v: Journal of Clinical Oncology. 23:8062-8062
8062 Background: BE, a monoclonal antibody that inhibits VEGF, prolongs survival in patients (pts) with metastatic colorectal cancer treated with 5FU chemotherapy. However, BE is associated with HT...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a132d774b4e9dce16114900546d56603
https://doi.org/10.1200/jco.2005.23.16_suppl.8062
Zobrazit plný text záznamu
8
Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung
Autor: Richard S. Cox, Linda Y. Chak, M A Tucker, Branimir I. Sikic, R C Horns
Publikováno v: Journal of Clinical Oncology. 2:385-390
A group of 158 patients with small cell carcinoma of the lung were followed for 174.5 person-years of observation to determine the risk of acute leukemia. Three cases of acute nonlymphocytic leukemia were observed at 2.3, 2.7, and 3.0 years. The rela
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f184200e95b925c2f8c808d02ccf881e
https://doi.org/10.1200/jco.1984.2.5.385
Zobrazit plný text záznamu
9
Gene amplification in a leukemic patient treated with methotrexate
Autor: R C Horns, W J Dower, R T Schimke
Publikováno v: Journal of Clinical Oncology. 2:2-7
Resistance to methotrexate (MTX) has been shown in mouse, hamster, and human cell lines grown in sequentially increased MTX concentrations to be due to increased dihydrofolate reductase (DHFR) synthesis and a proportional increase in DHFR gene copy n
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fbddaaefb3ed47676d157208f690340
https://doi.org/10.1200/jco.1984.2.1.2
Zobrazit plný text záznamu
10
Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma
Autor: S Olson, R N Buick, R T Schimke, Jeffrey M. Trent, R C Horns
Publikováno v: Journal of Clinical Oncology. 2:8-15
To analyze if methotrexate (MTX) resistance arises from gene amplification in a patient treated clinically with MTX, the cytogenetic and drug sensitivity profile of the tumor colony forming units (TCFUs) from a 58-year-old woman with stage III well-d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f10b34c5a9e42bc37da6075ddd4b4d1e
https://doi.org/10.1200/jco.1984.2.1.8
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje